Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF +10.11%77 3-Year Book Growth Rate is 6.80% as of Jun. 2026, which is 60% above its 10-year median of 4.25. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $15.35 (Fairly Valued). The stock has 4 warning signs investors should review. Among 912 Drug Manufacturers companies, Astellas Pharma ranks better than 58.77% on this metric.
During the past 12 months, Astellas Pharma's average Book Value per Share Growth Rate was 31.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 5.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 5.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Astellas Pharma was 10.90% per year. The lowest was 1.10% per year. And the median was 4.25% per year.
Astellas Pharma (OTCPK:ALPMF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Astellas Pharma 3-Year Book Growth Rate Related Terms
ALPMF vs LLY, JNJ, ABBV: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's 3-Year Book Growth Rate falls into.
Astellas Pharma 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 6.80% mean?
Astellas Pharma (ALPMF) has a 3-Year Book Growth Rate of 6.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Astellas Pharma and its competitors. This is 60% above median its historical median of 4.25. Over the past decade, Astellas Pharma's 3-Year Book Growth Rate has ranged from 1.10 to 10.90. According to the industry distribution chart, Astellas Pharma ranks #376 out of 912 companies in the Drug Manufacturers industry, placing it in the top 41.2%.
Is Astellas Pharma's 3-Year Book Growth Rate too high?
Astellas Pharma's current 3-Year Book Growth Rate of 6.80% is 60% above median its 10-year median of 4.25. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 10.90. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Astellas Pharma's value of 6.80% is 47.8% above this industry median. Based on the distribution chart, Astellas Pharma ranks #376 out of 912 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's 3-Year Book Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #376 out of 912 companies for 3-Year Book Growth Rate. This puts Astellas Pharma in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Astellas Pharma's value of 6.80% is 47.8% above this benchmark. Historically, Astellas Pharma's own 3-Year Book Growth Rate has ranged from 1.10 to 10.90 over the past decade. While the company's 10-year median is 4.25 vs. the industry median of 4.60, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current 3-Year Book Growth Rate of 6.80% is 47.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current 3-Year Book Growth Rate is 6.80%, which is 60% above median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $15.35, compared to a current price of $15.25 — trading 0.7% below its estimated fair value. The current 3-Year Book Growth Rate is 6.80%, which is 60% above median its 10-year median of 4.25 and 47.8% above the Drug Manufacturers industry median of 4.60. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current 3-Year Book Growth Rate is 6.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $15.25 is trading 0.7% below its estimated GF Value™ of $15.35.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
3-Year Book Growth Rate: 6.80% (60% above median its 10-year median of 4.25)
GF Value™: $15.35 vs. price of $15.25 (0.7% below fair value)
Industry Position: 47.8% above the Drug Manufacturers median (#376 of 912)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score
Get the complete analysis for ALPMF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
